Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Ruvolo G, Roccheri MC, Brucculeri AM, Longobardi S, Cittadini E, Bosco L. Lower sperm DNA fragmentation after r-FSH administration in functional hypogonadotropic hypogonadism. J Assist Reprod Genet 2013;30:497-503. [PMID: 23435529 DOI: 10.1007/s10815-013-9951-y] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2012] [Accepted: 01/28/2013] [Indexed: 01/09/2023] Open

For:	Ruvolo G, Roccheri MC, Brucculeri AM, Longobardi S, Cittadini E, Bosco L. Lower sperm DNA fragmentation after r-FSH administration in functional hypogonadotropic hypogonadism. J Assist Reprod Genet 2013;30:497-503. [PMID: 23435529 DOI: 10.1007/s10815-013-9951-y] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2012] [Accepted: 01/28/2013] [Indexed: 01/09/2023] Open

Number

Cited by Other Article(s)

Grande G, Graziani A, Scafa R, Garolla A, Santi D, Ferlin A. FSH Therapy in Male Factor Infertility: Evidence and Factors Which Might Predict the Response. Life (Basel) 2024;14:969. [PMID: 39202711 PMCID: PMC11355377 DOI: 10.3390/life14080969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2024] [Revised: 07/23/2024] [Accepted: 07/25/2024] [Indexed: 09/03/2024] Open

Abstract

Follicle-stimulating hormone (FSH) administration is applied in the management of subjects affected by hypogonadotropic hypogonadism. Whilst this application is widely recognized and established alone or in combination with human chorionic gonadotropin (hCG), a similar strategy is empirically advocated in idiopathic male factor infertility (MFI). In this setting, FSH therapy has been used to increase sperm quantity, quality, and pregnancy rate when FSH plasma concentrations are below 8 IU/L and when the seminal tract is not obstructed. In the literature, several studies suggested that giving FSH to patients with idiopathic MFI increases sperm count and motility, raising the overall pregnancy rate. However, this efficacy seems to be limited, and about 10-18 men should be treated to achieve one pregnancy. Thus, several papers suggest the need to move from a replacement approach to an overstimulating approach in the management of FSH therapy in idiopathic MFI. To this aim, it is imperative to determine some pharmacologic markers of FSH efficacy. Furthermore, it should be useful in clinical practice to distinguish, before starting the treatment, among patients who might respond or not to FSH treatment. Indeed, previous studies suggest that infertile men who have normal levels of gonadotropins in plasma might not respond to FSH treatment and about 50% of patients might be defined as "non-responders". For these reasons, identifying predictive markers of FSH action in spermatogenesis and clinical markers of response to FSH treatment is a fascinating area of study that might lead to new developments with the aim of achieving personalization of the treatment of male infertility. From this perspective, seminal parameters (i.e., spermatid count), testicular cytology, genetic assessment, and miRNA or protein markers in the future might be used to create a tailored FSH therapy plan. The personalization of FSH treatment is mandatory to minimize side effects, to avoid lost time with ineffective treatments, and to improve the efficacy, predicting the most efficient dose and the duration of the treatment. This narrative review's objective is to discuss the role of the different putative factors which have been proposed to predict the response to FSH treatment in idiopathic infertile men.

Collapse

Farkouh A, Agarwal A, Hamoda TAAAM, Kavoussi P, Saleh R, Zini A, Arafa M, Harraz AM, Gul M, Karthikeyan VS, Durairajanayagam D, Rambhatla A, Boitrelle F, Chung E, Birowo P, Toprak T, Ghayda RA, Cannarella R, Phuoc NHV, Dimitriadis F, Russo GI, Sokolakis I, Mostafa T, Makarounis K, Ziouziou I, Kuroda S, Bendayan M, Kaiyal RS, Japari A, Simopoulou M, Rocco L, Garrido N, Gherabi N, Bocu K, Kahraman O, Le TV, Wyns C, Tremellen K, Sarikaya S, Lewis S, Evenson DP, Ko E, Calogero AE, Bahar F, Martinez M, Crafa A, Nguyen Q, Ambar RF, Colpi G, Bakircioglu ME, Henkel R, Kandil H, Serefoglu EC, Alarbid A, Tsujimura A, Kheradmand A, Anagnostopoulou C, Marino A, Adamyan A, Zilaitiene B, Ozer C, Pescatori E, Vogiatzi P, Busetto GM, Balercia G, Elbardisi H, Akhavizadegan H, Sajadi H, Taniguchi H, Park HJ, Maldonado Rosas I, Al-Marhoon M, Sadighi Gilani MA, Alhathal N, Pinggera GM, Kothari P, Mogharabian N, Micic S, Homa S, Darbandi S, Long TQT, Zohdy W, Atmoko W, Sabbaghian M, Ibrahim W, Smith RP, Ho CCK, de la Rosette J, El-Sakka AI, Preto M, Zenoaga-Barbăroșie C, Abumelha SM, Baser A, Aydos K, Ramirez-Dominguez L, Kumar V, Ong TA, Mierzwa TC, Adriansjah R, Banihani SA, et alFarkouh A, Agarwal A, Hamoda TAAAM, Kavoussi P, Saleh R, Zini A, Arafa M, Harraz AM, Gul M, Karthikeyan VS, Durairajanayagam D, Rambhatla A, Boitrelle F, Chung E, Birowo P, Toprak T, Ghayda RA, Cannarella R, Phuoc NHV, Dimitriadis F, Russo GI, Sokolakis I, Mostafa T, Makarounis K, Ziouziou I, Kuroda S, Bendayan M, Kaiyal RS, Japari A, Simopoulou M, Rocco L, Garrido N, Gherabi N, Bocu K, Kahraman O, Le TV, Wyns C, Tremellen K, Sarikaya S, Lewis S, Evenson DP, Ko E, Calogero AE, Bahar F, Martinez M, Crafa A, Nguyen Q, Ambar RF, Colpi G, Bakircioglu ME, Henkel R, Kandil H, Serefoglu EC, Alarbid A, Tsujimura A, Kheradmand A, Anagnostopoulou C, Marino A, Adamyan A, Zilaitiene B, Ozer C, Pescatori E, Vogiatzi P, Busetto GM, Balercia G, Elbardisi H, Akhavizadegan H, Sajadi H, Taniguchi H, Park HJ, Maldonado Rosas I, Al-Marhoon M, Sadighi Gilani MA, Alhathal N, Pinggera GM, Kothari P, Mogharabian N, Micic S, Homa S, Darbandi S, Long TQT, Zohdy W, Atmoko W, Sabbaghian M, Ibrahim W, Smith RP, Ho CCK, de la Rosette J, El-Sakka AI, Preto M, Zenoaga-Barbăroșie C, Abumelha SM, Baser A, Aydos K, Ramirez-Dominguez L, Kumar V, Ong TA, Mierzwa TC, Adriansjah R, Banihani SA, Bowa K, Fukuhara S, Rodriguez Peña M, Moussa M, Ari UÇ, Cho CL, Tadros NN, Ugur MR, Amar E, Falcone M, Santer FR, Kalkanli A, Karna KK, Khalafalla K, Vishwakarma RB, Finocchi F, Giulioni C, Ceyhan E, Çeker G, Yazbeck C, Rajmil O, Yilmaz M, Altay B, Barrett TL, Ngoo KS, Roychoudhury S, Salvio G, Lin H, Kadioglu A, Timpano M, Avidor-Reiss T, Hakim L, Sindhwani P, Franco G, Singh R, Giacone F, Ruzaev M, Kosgi R, Sofikitis N, Palani A, Calik G, Kulaksız D, Jezek D, Al Hashmi M, Drakopoulos P, Omran H, Leonardi S, Celik-Ozenci C, Güngör ND, Ramsay J, Amano T, Sogutdelen E, Duarsa GWK, Chiba K, Jindal S, Savira M, Boeri L, Borges E, Gupte D, Gokalp F, Hebrard GH, Minhas S, Shah R, Global Andrology Forum. Controversy and Consensus on the Management of Elevated Sperm DNA Fragmentation in Male Infertility: A Global Survey, Current Guidelines, and Expert Recommendations. World J Mens Health 2023;41:809-847. [PMID: 37118965 PMCID: PMC10523126 DOI: 10.5534/wjmh.230008] [Show More Authors] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Revised: 01/18/2023] [Accepted: 01/27/2023] [Indexed: 04/30/2023] Open

Abstract

PURPOSE

Sperm DNA fragmentation (SDF) has been associated with male infertility and poor outcomes of assisted reproductive technology (ART). The purpose of this study was to investigate global practices related to the management of elevated SDF in infertile men, summarize the relevant professional society recommendations, and provide expert recommendations for managing this condition.

MATERIALS AND METHODS

An online global survey on clinical practices related to SDF was disseminated to reproductive clinicians, according to the CHERRIES checklist criteria. Management protocols for various conditions associated with SDF were captured and compared to the relevant recommendations in professional society guidelines and the appropriate available evidence. Expert recommendations and consensus on the management of infertile men with elevated SDF were then formulated and adapted using the Delphi method.

RESULTS

A total of 436 experts from 55 different countries submitted responses. As an initial approach, 79.1% of reproductive experts recommend lifestyle modifications for infertile men with elevated SDF, and 76.9% prescribe empiric antioxidants. Regarding antioxidant duration, 39.3% recommend 4-6 months and 38.1% recommend 3 months. For men with unexplained or idiopathic infertility, and couples experiencing recurrent miscarriages associated with elevated SDF, most respondents refer to ART 6 months after failure of conservative and empiric medical management. Infertile men with clinical varicocele, normal conventional semen parameters, and elevated SDF are offered varicocele repair immediately after diagnosis by 31.4%, and after failure of antioxidants and conservative measures by 40.9%. Sperm selection techniques and testicular sperm extraction are also management options for couples undergoing ART. For most questions, heterogenous practices were demonstrated.

CONCLUSIONS

This paper presents the results of a large global survey on the management of infertile men with elevated SDF and reveals a lack of consensus among clinicians. Furthermore, it demonstrates the scarcity of professional society guidelines in this regard and attempts to highlight the relevant evidence. Expert recommendations are proposed to help guide clinicians.

Collapse

Affiliation(s)

Ala’a Farkouh Global Andrology Forum, American Center for Reproductive Medicine, Moreland Hills, OH, USA
Ashok Agarwal Global Andrology Forum, American Center for Reproductive Medicine, Moreland Hills, OH, USA Cleveland Clinic Foundation, Cleveland, OH, USA
Taha Abo-Almagd Abdel-Meguid Hamoda Department of Urology, King Abdulaziz University, Jeddah, Saudi Arabia Department of Urology, Faculty of Medicine, Minia University, Minia, Egypt
Parviz Kavoussi Department of Reproductive Urology, Austin Fertility & Reproductive Medicine/Westlake IVF, Austin, TX, USA
Ramadan Saleh Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Sohag University, Sohag, Egypt Ajyal IVF Center, Ajyal Hospital, Sohag, Egypt
Armand Zini Department of Surgery, McGill University, Montreal, QC, Canada
Mohamed Arafa Department of Urology, Hamad Medical Corporation, Doha, Qatar Department of Andrology, Sexology & STIs, Cairo University, Cairo, Egypt Department of Urology, Weill Cornell Medical-Qatar, Doha, Qatar
Ahmed M. Harraz Urology Department, Urology and Nephrology Center, Mansoura University, Mansura, Egypt Department of Surgery, Urology Unit, Farwaniya Hospital, Farwaniya, Kuwait Department of Urology, Sabah Al Ahmad Urology Center, Kuwait City, Kuwait
Murat Gul Department of Urology, Selçuk University School of Medicine, Konya, Turkey
Vilvapathy Senguttuvan Karthikeyan Andrology Unit, Department of Urology, Apollo Hospitals, Chennai, India
Damayanthi Durairajanayagam Department of Physiology, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh Campus, Selangor, Malaysia
Amarnath Rambhatla Department of Urology, Henry Ford Health System, Vattikuti Urology Institute, Detroit, MI, USA
Florence Boitrelle Reproductive Biology, Fertility Preservation, Andrology, CECOS, Poissy Hospital, Poissy, France Department of Biology, Reproduction, Epigenetics, Environment and Development, Paris Saclay University, UVSQ, INRAE, BREED, Jouy-en-Josas, France
Eric Chung Department of Urology, Princess Alexandra Hospital, University of Queensland, Brisbane, QLD, Australia
Ponco Birowo Department of Urology, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
Tuncay Toprak Department of Urology, Fatih Sultan Mehmet Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
Ramy Abou Ghayda Urology Institute, University Hospitals, Case Western Reserve University, Cleveland, OH, USA
Rossella Cannarella Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy Department of Urology, Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, USA
Nguyen Ho Vinh Phuoc Department of Andrology, Binh Dan Hospital, Ho Chi Minh City, Vietnam Department of Urology and Andrology, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam
Fotios Dimitriadis Department of Urology, Aristotle University, School of Medicine, Thessaloniki,
Giorgio I. Russo Urology Section, University of Catania, Catania, Italy
Ioannis Sokolakis Department of Urology, Aristotle University, School of Medicine, Thessaloniki,
Taymour Mostafa Department of Andrology, Sexology & STIs, Cairo University, Cairo, Egypt
Konstantinos Makarounis Department of Urology and Andrology, Locus Medicus, Athens, Greece
Imad Ziouziou Department of Urology, College of Medicine and Pharmacy, Ibn Zohr University, Agadir, Morocco
Shinnosuke Kuroda Department of Urology, Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, USA
Marion Bendayan Reproductive Biology, Fertility Preservation, Andrology, CECOS, Poissy Hospital, Poissy, France
Raneen Sawaid Kaiyal Department of Urology, Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, USA
Andrian Japari Fertility Clinic, Telogorejo Hospital, Semarang, Indonesia
Mara Simopoulou Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
Lucia Rocco Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania Luigi Vanvitelli, Caserta, Italy
Nicolas Garrido IVI Foundation, Instituto de Investigación Sanitaria La Fe (IIS La Fe), Valencia, Spain
Nazim Gherabi Department of Urology, University of Algiers, Algiers, Algeria
Kadir Bocu Department of Urology, Silopi State Hospital, Sirnak, Turkey
Oguzhan Kahraman Department of Urology, Faculty of Medicine, Baskent University, Ankara, Turkey
Tan V. Le Department of Andrology, Binh Dan Hospital, Ho Chi Minh City, Vietnam Department of Urology and Andrology, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam
Christine Wyns Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
Kelton Tremellen Department of Obstetrics Gynaecology and Reproductive Medicine, Flinders University, South Australia, Australia
Selcuk Sarikaya Department of Urology, Gülhane Research and Training Hospital, University of Health Sciences, Ankara, Turkey
Sheena Lewis Examen Lab Ltd., Northern Ireland, UK
Donald P. Evenson SCSA Diagnostics, Brookings, SDUSA, USA
Edmund Ko Department of Urology, Loma Linda University Health, Loma Linda, CA, USA
Aldo E. Calogero Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
Fahmi Bahar Andrology Section, Siloam Sriwijaya Hospital, Palembang, Indonesia
Marlon Martinez Section of Urology, Department of Surgery, University of Santo Tomas Hospital, Manila, Philippines
Andrea Crafa Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
Quang Nguyen Center for Andrology and Sexual Medicine, Viet Duc University Hospital, Hanoi, Vietnam Department of Urology, Andrology and Sexual Medicine, University of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam
Rafael F. Ambar Department of Urology, Centro Universitario em Saude do ABC, Santo André, Brazil Andrology Group at Ideia Fertil Institute of Human Reproduction, Santo André, Brazil
Giovanni Colpi Andrology and IVF Center, Next Fertility Procrea, Lugano, Switzerland
Mustafa Emre Bakircioglu SENSART Clinic, Urology, Fulya, Istanbul, Turkey
Ralf Henkel Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK Department of Medical Bioscience, University of the Western Cape, Bellville, South Africa
Hussein Kandil Fakih IVF Fertility Center, Abu Dhabi, UAE
Ege Can Serefoglu Department of Urology, Biruni University School of Medicine, Istanbul, Turkey
Abdullah Alarbid Department of Surgery, Urology Unit, Farwaniya Hospital, Farwaniya, Kuwait
Akira Tsujimura Department of Urology, Juntendo University Urayasu Hospital, Chiba, Japan
Alireza Kheradmand Urology Department, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Christina Anagnostopoulou Unit of Reproductive Medicine-EmbryoART, Leto Maternity Hospital, Athens, Greece
Angelo Marino ANDROS Day Surgery Clinic, Reproductive Medicine Unit, Palermo, Italy
Aram Adamyan IVF Department, Astghik Medical Center, Yerevan, Armenia
Birute Zilaitiene Institute of Endocrinology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
Cevahir Ozer Department of Urology, Faculty of Medicine, Baskent University, Ankara, Turkey
Edoardo Pescatori Andrology and Reproductive Medicine Unit, Gynepro Medical, Bologna, Italy
Paraskevi Vogiatzi Andromed Health & Reproduction, Fertility & Reproductive Health Diagnostic Center, Athens, Greece
Gian Maria Busetto Department of Urology and Renal Transplantation, University of Foggia, Policlinico Riuniti, Foggia, Italy
Giancarlo Balercia Department of Endocrinology, Polytechnic University of Marche, Ancona, Italy
Haitham Elbardisi Department of Urology, Hamad Medical Corporation, Doha, Qatar Department of Andrology, Sexology & STIs, Cairo University, Cairo, Egypt
Hamed Akhavizadegan Department of Urology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
Hesamoddin Sajadi Department of Andrology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Teheran, Iran
Hisanori Taniguchi Department of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan
Hyun Jun Park Department of Urology, Pusan National University School of Medicine, Busan, Korea Medical Research Institute of Pusan National University Hospital, Busan, Korea
Israel Maldonado Rosas IVF Laboratory, CITMER Reproductive Medicine, Mexico City, Mexico
Mohamed Al-Marhoon Division of Urology, Department of Surgery, Sultan Qaboos University, Muscat, Sultanate of Oman
Mohammad Ali Sadighi Gilani Department of Andrology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Teheran, Iran
Naif Alhathal King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Germar-Michael Pinggera Department of Urology, Innsbruck Medical University, Innsbruck, Austria
Priyank Kothari Department of Urology, Topiwala National Medical College, B.Y.L Nair Ch Hospital, Mumbai, India
Nasser Mogharabian Sexual Health and Fertility Research Center, Shahroud University of Medical Sciences, Shahroud, Iran
Sava Micic Department of Andrology, Uromedica Polyclinic, Belgrade, Serbia
Sheryl Homa Department of Biosciences, University of Kent, Canterbury, UK
Sara Darbandi Fetal Health Research Center, Hope Generation Foundation, Tehran, Iran Gene Therapy and Regenerative Medicine Research Center, Hope Generation Foundation, Tehran, Iran
Tran Quang Tien Long Department of Obstetrics and Gynecology, Hanoi Obstetrics and Gynecology Hospital, Hanoi, Vietnam
Wael Zohdy Department of Andrology, Sexology & STIs, Cairo University, Cairo, Egypt
Widi Atmoko Department of Urology, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
Marjan Sabbaghian Department of Andrology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Teheran, Iran
Wael Ibrahim Department of Obstetrics Gynaecology and Reproductive Medicine, Fertility Care Center in Cairo, Cairo, Egypt
Ryan P. Smith Department of Urology, University of Virginia School of Medicine, Virginia, USA
Christopher Chee Kong Ho Department of Surgery, School of Medicine, Taylor’s University, Subang Jaya, Selangor, Malaysia
Jean de la Rosette Department of Urology, Istanbul Medipol University, Istanbul, Turkey
Ahmed I. El-Sakka Department of Urology, Suez Canal University, Ismailia, Egypt
Mirko Preto Department of Urology, University of Turin, Turin, Italy
Cătălina Zenoaga-Barbăroșie Department of Genetics, Faculty of Biology, University of Bucharest, Bucharest, Romania
Saad Mohammed Abumelha Division of Urology, Department of Surgery, King Abdulaziz Medical City, Riyadh, Saudi Arabia
Aykut Baser Department of Urology, Bandirma Onyedi Eylül University, Balikesir, Turkey
Kaan Aydos Department of Urology, Ankara University, Ankara, Turkey
Liliana Ramirez-Dominguez IVF Laboratory, CITMER Reproductive Medicine, Mexico City, Mexico
Vijay Kumar Department of Microbiology, Kurukshetra University, Kurukshetra, India
Teng Aik Ong Department of Surgery, University of Malaya, Kuala Lumpur, Malaysia
Tiago Cesar Mierzwa Androlab, Fertility Clinic, Curitiba, PR, Brazil
Ricky Adriansjah Department of Urology, Faculty of Medicine of Padjadjaran University, Hasan Sadikin General Hospital, Bandung, Indonesia
Saleem A. Banihani Department of Medical Laboratory Sciences, Jordan University of Science and Technology, Irbid, Jordan
Kasonde Bowa Department of Urology, University of Lusaka, Lusaka, Zambia
Shinichiro Fukuhara Department of Urology, Graduate School of Medicine, Osaka University, Osaka, Japan
Marcelo Rodriguez Peña Instituto de Ginecologia y Fertilidad (IFER), Buenos Aire, Argentina
Mohamad Moussa Department of Urology, Lebanese University, Beirut, Lebanon Department of Urology, Al Zahraa Hospital, UMC, Lebanon
Umut Çağın Ari Department of Reproduction, Kafkas University, Kars, Turkey
Chak-Lam Cho S. H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong
Nicholas N. Tadros Division of Urology, Southern Illinois University, Springfield, IL, USA
Muhammet Rasit Ugur IVF Michigan, Bloomfield Hills, MI, USA
Edouard Amar American Hospital of Paris, Paris, France
Marco Falcone Department of Urology, Molinette Hospital, A.O.U. Città della Salute e della Scienza, University of Turin, Torino, Italy
Frederic Romain Santer Department of Urology, Innsbruck Medical University, Innsbruck, Austria
Arif Kalkanli Department of Urology, Taksim Education and Research Hospital, Istanbul, Turkey
Keshab Kumar Karna Department of Molecular Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA, USA
Kareim Khalafalla Department of Urology, Hamad Medical Corporation, Doha, Qatar Urology Department, University of Texas McGovern Medical School, Houston, TX, USA Urology Department, MD Anderson Cancer Center, Houston, TX, USA
Ranjit B. Vishwakarma Division of Andrology, Department of Urology, Lilavati Hospital and Research Centre, Mumbai, India
Federica Finocchi Department of Endocrinology, Polytechnic University of Marche, Ancona, Italy
Carlo Giulioni Department of Urology, Polytechnic University of Marche Region, Ancona, Italy
Erman Ceyhan Department of Urology, Faculty of Medicine, Baskent University, Ankara, Turkey
Gökhan Çeker Department of Urology, Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey
Chadi Yazbeck Obstetrics Gynecology and Reproductive Medicine, Reprogynes Medical Institute, Paris, France
Osvaldo Rajmil Department of Andrology, Fundacio Puigvert, Barcelona, Spain
Mehmet Yilmaz Asklepios Clinic Triberg, Urology, Freiburg, Germany
Baris Altay Department of Urology, Ege University, Izmir, Turkey
Trenton L. Barrett Perth Urology Clinic, Perth, WA, Australia
Kay Seong Ngoo Hospital Angkatan Tentera Tuanku Mizan, Kuala Lumpur, Malaysia
Shubhadeep Roychoudhury Department of Life Science and Bioinformatics, Assam University, Silchar, India
Gianmaria Salvio Department of Endocrinology, Polytechnic University of Marche, Ancona, Italy
Haocheng Lin Department of Urology, Peking University Third Hospital, Beijing, China
Ates Kadioglu Section of Andrology, Department of Urology, Istanbul University, Istanbul, Turkey
Massimiliano Timpano Department of Urology, Molinette Hospital, A.O.U. Città della Salute e della Scienza, University of Turin, Torino, Italy
Tomer Avidor-Reiss Department of Biological Sciences, University of Toledo, Toledo, OH, USA Department of Urology and Transplantation, University of Toledo, Toledo, OH, USA
Lukman Hakim Department of Urology, Universitas Airlangga, Rumah Sakit Universitas Airlangga Teaching Hospital, Surabaya, Indonesia
Puneet Sindhwani Department of Urology, Universitas Airlangga, Rumah Sakit Universitas Airlangga Teaching Hospital, Surabaya, Indonesia
Giorgio Franco Department of Urology, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
Rajender Singh Division of Endocrinology, Central Drug Research Institute, Lucknow, India
Filippo Giacone Centro HERA, Unità di Medicina della Riproduzione, Sant’Agata Li Battiati, Catania, Italy
Mikhail Ruzaev Private Clinic, Moscow, Russia
Raghavender Kosgi Department of Urology, Andrology and Renal Transplant, AIG Hospitals, Hyderabad, India
Nikolaos Sofikitis Department of Urology, Ioannina University School of Medicine, Ioannina, Greece
Ayad Palani Research Centre, University of Garmian, Kalar, Iraq
Gokhan Calik Department of Urology, Istanbul Medipol University, Istanbul, Turkey
Deniz Kulaksız Department of Obstetrics and Gynecology, University of Health Sciences Kanuni Training and Research Hospital, Trabzon, Turkey
Davor Jezek Department for Transfusion Medicine and Transplantation Biology, Reproductive Tissue Bank, University Hospital Zagreb, Zagreb, Croatia
Manaf Al Hashmi Department of Urology, Burjeel Hospital, Abu Dhabi, UAE Department of Urology, College of Medicine and Health Science, Khalifa University, Abu Dhabi, UAE
Panagiotis Drakopoulos Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium IVF Athens, Athens, Greece
Huda Omran Al Aljenan Medical Center, Pulse Health Training Center, Manama, Kingdom of Bahrain
Sofia Leonardi Central Laboratory, Hospital Público Materno Infantil de Salta, Salta, Argentina
Ciler Celik-Ozenci Department of Histology and Embryology, Faculty of Medicine, Koç University, Istanbul, Turkey
Nur Dokuzeylül Güngör Department of Obstetrics and Gynecology, Reproductive Endocrinology and IVF Unit, School of Medicine, Bahcesehir University, Istanbul, Turkey
Jonathan Ramsay Department of Andrology, Hammersmith Hospital, London, UK
Toshiyasu Amano Department of Urology, Nagano Red Cross Hospital, Nagano, Japan
Emrullah Sogutdelen Department of Urology, Bolu Abant Izzet Baysal University, Bolu, Turkey
Gede Wirya Kusuma Duarsa Department of Urology, Udayana University, Denpasar, Indonesia
Koji Chiba Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
Sunil Jindal Department of Andrology and Reproductive Medicine, Jindal Hospital, Meerut, India
Missy Savira Department of Urology, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
Luca Boeri Department of Urology, IRCCS Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy
Edson Borges Fertility Assisted Fertilization Center, São Paulo, Brazil
Deepak Gupte Department of Urology, Bombay Hospital and Medical Research Center, Mumbai, India
Fatih Gokalp Department of Urology, Hatay Mustafa Kemal University, Antakya, Turkey
Guadalupe Hernández Hebrard IVF Laboratory, CITMER Reproductive Medicine, Mexico City, Mexico
Suks Minhas Division of Surgery, Department of Surgery and Cancer, Imperial College, London, UK
Rupin Shah Division of Andrology, Department of Urology, Lilavati Hospital and Research Centre, Mumbai, India
Global Andrology Forum

Collapse

Cannarella R, La Vignera S, Condorelli RA, Mongioì LM, Calogero AE. FSH dosage effect on conventional sperm parameters: a meta-analysis of randomized controlled studies. Asian J Androl 2021;22:309-316. [PMID: 31274479 PMCID: PMC7275804 DOI: 10.4103/aja.aja_42_19] [Citation(s) in RCA: 37] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open

Retrospective Monocentric Clinical Study on Male Infertility: Comparison between Two Different Therapeutic Schemes Using Follicle-Stimulating Hormone. J Clin Med 2021;10:jcm10122665. [PMID: 34204212 PMCID: PMC8233778 DOI: 10.3390/jcm10122665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2021] [Revised: 06/07/2021] [Accepted: 06/15/2021] [Indexed: 11/17/2022] Open

Abstract

Follicle-stimulating hormone (FSH) is a therapeutic option in patients with idiopathic oligozoospermia and normal FSH serum levels. However, few studies have evaluated which dose of FSH is more effective. The aim of this study was to compare the clinical efficacy of the two most frequently used FSH treatment regimens: 75 IU daily vs. 150 IU three times a week. Patients were retrospectively assigned to two groups. The first group (n = 24) was prescribed highly purified FSH (hpFSH) 75 IU/daily (Group A), and the second group (n = 24) was prescribed hpFSH 150 IU three times a week (Group B) for three months. Before and after treatment, each patient underwent semen analysis, evaluation of the percentage of DNA-fragmented spermatozoa, assessment of testicular volume (by ultrasonography), and measurement of FSH and total testosterone (TT) serum levels. Treatment with hpFSH significantly improved conventional sperm parameters. In detail, sperm concentration increased significantly after treatment only in Group A, whereas total sperm count, percentage of spermatozoa with progressive motility, normal morphology, or alive improved significantly in both groups. Interestingly, the percentage of sperm DNA fragmentation decreased significantly in both groups after treatment with hpFSH. FSH serum levels were expectably higher at the end of the treatment than before hpFSH was administered to both groups. Remarkably, TT serum levels only increased significantly in Group A. Finally, testicular volume was significantly higher in Group A after treatment, while it did not change significantly compared to baseline in Group B. The percentage of FSH responders did not differ significantly between the two groups (8/24 vs. 6/24). The daily administration of hpFSH 75 IU seems more effective than using 150 IU three times a week. However, this therapeutic scheme implies a higher number of injections and slightly higher costs.

Collapse

Ferrigno A, Ruvolo G, Capra G, Serra N, Bosco L. Correlation between the DNA fragmentation index (DFI) and sperm morphology of infertile patients. J Assist Reprod Genet 2021;38:979-986. [PMID: 33532883 PMCID: PMC8079535 DOI: 10.1007/s10815-021-02080-w] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Accepted: 01/19/2021] [Indexed: 11/18/2022] Open

Verdi A, Nasr-Esfahani MH, Forouzanfar M, Tavalaee M. The Effect of Recombinant Human Follicle-Stimulating Hormone on Sperm Quality, Chromatin Status and Clinical Outcomes of Infertile Oligozoospermic Men Candidate for Intracytoplasmic Sperm Injection: A Randomized Clinical Trial. INTERNATIONAL JOURNAL OF FERTILITY & STERILITY 2021;15:1-7. [PMID: 33497040 PMCID: PMC7838760 DOI: 10.22074/ijfs.2021.6210] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/08/2019] [Accepted: 07/11/2020] [Indexed: 01/18/2023]

Abstract

Background

Follicle-stimulating hormone (FSH) plays a crucial role in spermatogenesis; in this study, we assessed the effect of recombinant human FSH (rhFSH) on sperm parameters, chromatin status and clinical outcomes of infer- tile oligozoospermic men candidates for intracytoplasmic sperm injection (ICSI).

Materials and Methods

This interventional randomized clinical trials (IRCT) included 40 infertile oligozoospermic men undergoing ICSI. These individuals were randomized into two groups: 20 men received rhFSH drug for three months and the other 20 men who did not receive rhFSH drug were considered the control group. Before and 3 months after treatment initiation, sperm parameters (using computer-assisted semen analysis) and chromatin status [using chromomycin A3, aniline blue, and sperm chromatin dispersion (SCD) tests] were assessed in these individuals. Fur- thermore, hormonal profile was assessed using enzyme-linked immunosorbent assay (ELISA). Clinical outcomes of ICSI were also compared between the two groups.

Results

The rhFSH treated group showed a significant increase in the level of FSH, luteinizing hormone (LH), tes- tosterone (T) and prolactin (PRL), as well as significant improvements in sperm parameters compared to the control group. Also, after administration of rhFSH, there was asignificant reduction in the percentage of sperm DNA damage, protamine deficiency and chromatin immaturity, while such a reduction in these parameters was not observed in the control group. Moreover, the percentage of embryos with grade Aquality, was significantly higher in the rhFSH group compared to the control group. The pregnancy rate in the rhFSH group was higher than the control group but the dif- ference was insignificant.

Conclusion

Administration of rhFSH improves sperm quality in infertile oligozoospermic men and results in higher rates of good quality embryos post-ICSI (Registration number: IRCT20170923036334N2).

Collapse

Chesnokova V, Melmed S. Peptide Hormone Regulation of DNA Damage Responses. Endocr Rev 2020;41:bnaa009. [PMID: 32270196 PMCID: PMC7279704 DOI: 10.1210/endrev/bnaa009] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/14/2019] [Accepted: 04/06/2020] [Indexed: 12/13/2022]

Follicle-Stimulating Hormone Treatment and Male Idiopathic Infertility: Effects on Sperm Parameters and Oxidative Stress Indices according to FSHR c. 2039 A/G and c. -29 G/A Genotypes. J Clin Med 2020;9:jcm9061690. [PMID: 32498268 PMCID: PMC7356235 DOI: 10.3390/jcm9061690] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Revised: 05/22/2020] [Accepted: 05/26/2020] [Indexed: 12/23/2022] Open

Esteves SC, Santi D, Simoni M. An update on clinical and surgical interventions to reduce sperm DNA fragmentation in infertile men. Andrology 2019;8:53-81. [DOI: 10.1111/andr.12724] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2019] [Revised: 09/17/2019] [Accepted: 10/08/2019] [Indexed: 12/18/2022]

Muratori M, De Geyter C. Chromatin condensation, fragmentation of DNA and differences in the epigenetic signature of infertile men. Best Pract Res Clin Endocrinol Metab 2019;33:117-126. [PMID: 30420311 DOI: 10.1016/j.beem.2018.10.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]

Barbonetti A, Calogero AE, Balercia G, Garolla A, Krausz C, La Vignera S, Lombardo F, Jannini EA, Maggi M, Lenzi A, Foresta C, Ferlin A. The use of follicle stimulating hormone (FSH) for the treatment of the infertile man: position statement from the Italian Society of Andrology and Sexual Medicine (SIAMS). J Endocrinol Invest 2018;41:1107-1122. [PMID: 29392544 DOI: 10.1007/s40618-018-0843-y] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/28/2017] [Accepted: 01/27/2018] [Indexed: 12/18/2022]

Sperm DNA fragmentation index as a promising predictive tool for male infertility diagnosis and treatment management – meta-analyses. Reprod Biomed Online 2018;37:315-326. [DOI: 10.1016/j.rbmo.2018.06.023] [Citation(s) in RCA: 92] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2017] [Revised: 06/21/2018] [Accepted: 06/22/2018] [Indexed: 11/17/2022]

Irani M, O'Neill C, Palermo GD, Xu K, Zhang C, Qin X, Zhan Q, Clarke RN, Ye Z, Zaninovic N, Rosenwaks Z. Blastocyst development rate influences implantation and live birth rates of similarly graded euploid blastocysts. Fertil Steril 2018;110:95-102.e1. [PMID: 29908774 DOI: 10.1016/j.fertnstert.2018.03.032] [Citation(s) in RCA: 69] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2018] [Revised: 03/12/2018] [Accepted: 03/19/2018] [Indexed: 10/14/2022]

Bosco L, Notari T, Ruvolo G, Roccheri MC, Martino C, Chiappetta R, Carone D, Lo Bosco G, Carrillo L, Raimondo S, Guglielmino A, Montano L. Sperm DNA fragmentation: An early and reliable marker of air pollution. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY 2018;58:243-249. [PMID: 29448163 DOI: 10.1016/j.etap.2018.02.001] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/20/2017] [Revised: 01/31/2018] [Accepted: 02/03/2018] [Indexed: 05/25/2023]

Colacurci N, De Leo V, Ruvolo G, Piomboni P, Caprio F, Pivonello R, Papaleo E, La Verde E, Depalo R, Lispi M, Longobardi S, Paoli D, Pallotti F, Lombardo F. Recombinant FSH Improves Sperm DNA Damage in Male Infertility: A Phase II Clinical Trial. Front Endocrinol (Lausanne) 2018;9:383. [PMID: 30042737 PMCID: PMC6048873 DOI: 10.3389/fendo.2018.00383] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/05/2018] [Accepted: 06/22/2018] [Indexed: 11/13/2022] Open

Abstract

UNLABELLED

Background and objectives: Male infertility is a global health dilemma and Follicle-Stimulating Hormone (FSH) administration has shown promising results. Several studies showed that infertile men with normal semen parameters have low levels of DNA damage while infertile men with abnormal semen parameters have more damage at the DNA level. Sperm DNA damage may affect the reproductive outcome and has been associated with failure in the achievement of competent embryos and pregnancy fulfillment. The aim of this study was to evaluate whether the administration of recombinant FSH (Gonal-f® PEN 900 IU) could improve sperm DNA fragmentation in men with infertility. The secondary endpoints of this study were to evaluate the FSH effects on sperm parameters and hormonal assets. Methods: A longitudinal, prospective, multicenter, open-label clinical trial was carried out. Infertile couples were recruited from six Italian Reproductive Medical Centers and 115 infertile men were enrolled for this study. All participants were treated with subcutaneous injections of Gonal-f® 150 IU every other day, within a 3 month-time frame. The semen samples were examined in accordance to the 2010 World Health Organization criteria. Sperm DNA Fragmentation (DFI) was determined by fluorescence microscopy using terminal deoxynucleotidyl transferase-mediated d-UTP Nick-end Labeling (TUNEL) assay. Statistical analysis was performed using both the t-test for paired samples and the Wilcoxon signed-rank test. Results: FSH administration improved DFI in 67% of patients, with an average decrease of 35.4% compared to the baseline. This improvement is more evident in men with basal DFI lower than 17% and in those with FSH basal levels between 2.16 and 4.27 IU/L. In addition, FSH enhanced the gonadal function, increasing the hormones AMH and Inhibin B and semen parameters. Limitation of these results are represented by the absence of a placebo group and of FSHR genotype stratification sub-analysis. Conclusion: Recombinant FSH 150 IU is well tolerated and effective in eliciting a significant DFI reduction as well as in improving gonadal function.

TRIAL REGISTRATION

EUDRACT Number 2010-020196-23. Registred 14 April 2011.

Collapse

Mohammadghasemi F, Mahmoudi-Lafout F. Effect of graded doses of acetylsalicylic acid on sperm chromatin integrity and maturity of germinal epithelium in adult male mouse. ASIAN PACIFIC JOURNAL OF REPRODUCTION 2018. [DOI: 10.4103/2305-0500.241179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open

Muratori M, Baldi E. Effects of FSH on Sperm DNA Fragmentation: Review of Clinical Studies and Possible Mechanisms of Action. Front Endocrinol (Lausanne) 2018;9:734. [PMID: 30619081 PMCID: PMC6297197 DOI: 10.3389/fendo.2018.00734] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2018] [Accepted: 11/19/2018] [Indexed: 12/17/2022] Open

Muratori M, Baldi E. Some relevant points on sperm DNA fragmentation tests. Transl Androl Urol 2017;6:S560-S563. [PMID: 29082178 PMCID: PMC5643625 DOI: 10.21037/tau.2017.03.47] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open

Relationship between apoptosis and survival molecules in human cumulus cells as markers of oocyte competence. ZYGOTE 2017;25:583-591. [PMID: 28786369 DOI: 10.1017/s0967199417000429] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]

Garolla A, Ghezzi M, Cosci I, Sartini B, Bottacin A, Engl B, Di Nisio A, Foresta C. FSH treatment in infertile males candidate to assisted reproduction improved sperm DNA fragmentation and pregnancy rate. Endocrine 2017;56:416-425. [PMID: 27465288 DOI: 10.1007/s12020-016-1037-z] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/03/2016] [Accepted: 06/23/2016] [Indexed: 12/27/2022]

Abstract

The purpose of this study is to evaluate whether follicle-stimulating hormone treatment improves sperm DNA parameters and pregnancy outcome in infertile male candidates to in-vitro fertilization.Observational study in 166 infertile male partners of couples undergoing in-vitro fertilization. Eighty-four patients were receiving follicle-stimulating hormone treatment (cases) and 82 refused treatment (controls). Semen parameters, sexual hormones, and sperm nucleus (fluorescence in-situ hybridization, acridine orange, TUNEL, and γH2AX) were evaluated at baseline (T0) and after 3 months (T1), when all subjects underwent assisted reproduction techniques. Statistical analysis was performed by analysis of variance.Compared to baseline, cases showed significant improvements in seminal parameters and DNA fragmentation indexes after follicle-stimulating hormone therapy (all P < 0.05), whereas no changes were observed in controls. Within cases, follicle-stimulating hormone treatment allowed to perform intrauterine insemination in 35 patients with a pregnancy rate of 23.2 %. Intracytoplasmic sperm injection was performed in all controls and in 49 patients from cases, with pregnancy rates of 23.2 and 40.8 %, respectively (P < 0.05). After 3 months (T0 vs. T1) of follicle-stimulating hormone therapy, cases with positive outcome had reduced DNA fragmentation index and lower double strand breaks (P < 0.05 and P < 0.001 vs. negative outcome, respectively).In this observational study, we showed that follicle-stimulating hormone treatment improves sperm DNA fragmentation, which in turn leads to increased pregnancy rates in infertile males undergoing in-vitro fertilization. In particular, double strand breaks (measured with γH2AX test) emerged as the most sensible parameter to follicle-stimulating hormone treatment in predicting reproductive outcome.

Collapse

Casamonti E, Vinci S, Serra E, Fino MG, Brilli S, Lotti F, Maggi M, Coccia ME, Forti G, Krausz C. Short-term FSH treatment and sperm maturation: a prospective study in idiopathic infertile men. Andrology 2017;5:414-422. [DOI: 10.1111/andr.12333] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2016] [Revised: 12/16/2016] [Accepted: 01/07/2017] [Indexed: 12/11/2022]

Bertrand-Delepine J, Leroy C, Rigot JM, Catteau-Jonard S, Dewailly D, Robin G. Stimulation de la spermatogenèse : pour qui ? Pourquoi ? Comment ? ACTA ACUST UNITED AC 2016;44:505-16. [DOI: 10.1016/j.gyobfe.2016.05.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2016] [Accepted: 05/24/2016] [Indexed: 12/23/2022]

Marchiani S, Tamburrino L, Muratori M, Baldi E. New insights in sperm biology: How benchside results in the search for molecular markers may help understand male infertility. World J Transl Med 2016;5:26-36. [DOI: 10.5528/wjtm.v5.i1.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/04/2015] [Revised: 01/22/2016] [Accepted: 02/17/2016] [Indexed: 02/06/2023] Open

Caprio F, De Franciscis P, Trotta C, Ianniello R, Mele D, Colacurci N. Seminal anti-Müllerian hormone levels during recombinant human follicle-stimulating hormone treatment in men with idiopathic infertility undergoing assisted reproduction cycles. Andrology 2015. [DOI: 10.1111/andr.12065] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]